110-17-8
110-17-8
Chemical Structure
Fumaric acid
- CAS No.: 110-17-8
- Formula:C4H4O4
- Molecular Weight:116.07
IUPAC Name: fumaric acid
InChIKey: VZCYOOQTPOCHFL-OWOJBTEDSA-N
SMILES: O=C(O)/C=C/C(O)=O
Biological Activity: Fumaric acid is an unsaturated dicarbonic acid, an intermediate product of the citric acid cycle that provides intracellular energy in the form of ATP. Fumaric acid exerts anti-inflammatory effects by inhibiting the NF-κB signaling pathway dependent on p38 MAPK. Fumaric acid can be used in the study of pregnancy-induced hypertension[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Fumaric acid | 99.91% | Fumaric acid is an unsaturated dicarbonic acid, an intermediate product of the citric acid cycle that provides intracellular energy in the form of ATP. Fumaric acid exerts anti-inflammatory effects by inhibiting the NF-κB signaling pathway dependent on p38 MAPK. Fumaric acid can be used in the study of pregnancy-induced hypertension. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fumaric acid (Standard) | 99.93% | Fumaric acid (Standard) is the analytical standard of Fumaric acid. This product is intended for research and analytical applications. Fumaric acid is an unsaturated dicarbonic acid, an intermediate product of the citric acid cycle that provides intracellular energy in the form of ATP. Fumaric acid exerts anti-inflammatory effects by inhibiting the NF-κB signaling pathway dependent on p38 MAPK. Fumaric acid can be used in the study of pregnancy-induced hypertension. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fumaric acid-13C2 | 99.9% | Fumaric acid-13C2 is the 13C-labeled Fumaric acid (HY-W015883). Fumaric acid is an unsaturated dicarbonic acid, an intermediate product of the citric acid cycle that provides intracellular energy in the form of ATP. Fumaric acid exerts anti-inflammatory effects by inhibiting the NF-κB signaling pathway dependent on p38 MAPK. Fumaric acid can be used in the study of pregnancy-induced hypertension. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fumaric acid-13C2,d2 | 98.00% | Fumaric acid-13C2,d2 is the deuterium and 13C labeled Fumaric acid. Fumaric acid, associated with fumarase deficiency, is identified as an oncometabolite or an endogenous, cancer causing metabolite. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fumaric acid-d4 | 98% | Fumaric acid-d4 is the deuterium labeled Fumaric acid. Fumaric acid, associated with fumarase deficiency, is identified as an oncometabolite or an endogenous, cancer causing metabolite. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fumaric acid-13C4 | 98.0% | Fumaric acid-13C4 is the 13C-labeled Fumaric acid. Fumaric acid, associated with fumarase deficiency, is identified as an oncometabolite or an endogenous, cancer causing metabolite. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fumaric acid-d2 | 99.50% | Fumaric acid-d2 is the deuterium labeled Fumaric acid. Fumaric acid, associated with fumarase deficiency, is identified as an oncometabolite or an endogenous, cancer causing metabolite. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fumaric acid2,3-13C2 disodium | 99% | Fumaric acid2,3-13C2 (disodium) is the deuterium labeled Fumaric acid disodium. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Whelan DT, et al. Fumaric aciduria: a new organic aciduria, associated with mental retardation and speech impairment. Clin Chim Acta. 1983 Aug 31;132(3):301-8. [Content Brief]
- [2]. Roh KB, et al. Fumaric acid attenuates the eotaxin-1 expression in TNF-α-stimulated fibroblasts by suppressing p38 MAPK-dependent NF-κB signaling. Food Chem Toxicol. 2013 Aug;58:423-31. [Content Brief]
- [3]. Zhou Y, et al. Fumaric acid and succinic acid treat gestational hypertension by downregulating the expression of KCNMB1 and TET1. Exp Ther Med. 2021 Oct;22(4):1072. [Content Brief]
